Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Oncology Therapeutics, Inc. (BBOT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BBOT is a clinical-stage biopharmaceutical company listed on the Nasdaq Global Market under the symbol BBOT and based in South San Francisco, California. Its filings offer detail on the company’s financial condition, clinical development activities, and key corporate events related to its focus on RAS and PI3Kα malignancies.
Among the filings, investors can find Current Reports on Form 8-K, such as the report dated November 12, 2025, in which the company furnished a press release announcing its financial results for the quarter ended September 30, 2025. That 8-K illustrates how BBOT uses SEC reports to communicate quarterly results, pipeline progress, and information about its debut as a publicly traded company and business combination with Helix Acquisition Corp. II, as described in the attached press release.
In addition to 8-Ks, users can expect access to other core filing types typically used by clinical-stage biopharmaceutical issuers, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and registration statements and proxy materials, where applicable. These documents collectively describe BBOT’s research and development spending, its clinical programs such as ONKORAS-101, KONQUER-101, and BREAKER-101, and the risks and uncertainties the company associates with its RAS and PI3Kα-targeted pipeline.
Stock Titan’s platform associates these filings with AI-powered tools that can help summarize lengthy documents, highlight key sections, and make it easier to locate information on topics such as BBOT’s financial results, clinical trial updates, and material corporate transactions as disclosed in its SEC reports.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of common stock for resale by selling securityholders under a post-effective amendment to its Form S-1. The registration covers (i) up to 24,343,711 PIPE Shares, (ii) up to 4,648,186 shares issued to the Sponsor and certain Helix initial shareholders, (iii) up to 32,155,445 shares issued or issuable to certain equity holders in the Business Combination, and (iv) 1,907,207 Options exercisable at $1.02–$7.88 per share.
The company will not receive proceeds from resale by the selling securityholders, except to the extent Options are exercised for cash. Sales may occur from time to time after this Registration Statement becomes effective. This amendment incorporates the company’s Form 10-K for the fiscal year ended December 31, 2025 and states no additional securities are being registered under this amendment.
BridgeBio Oncology Therapeutics, Inc. executive Marc Cobo, the Principal Accounting Officer, reported his initial ownership position on a Form 3. He directly holds 5,431 shares of Common Stock, which include 5,227 unvested restricted stock units, each representing a contingent right to receive one share upon vesting.
He also holds stock options covering 25,125 shares of Common Stock at an exercise price of $10.19 per share expiring on March 9, 2036, and options covering 129,090 shares at an exercise price of $9.59 per share expiring on August 25, 2035. These equity awards vest over time, subject to his continuous service with the company.
BridgeBio Oncology Therapeutics, Inc. executive Elmelech Idan, the COO and Principal Financial Officer, filed an initial ownership report. He holds 14,838 shares of Common Stock, which includes 14,232 unvested restricted stock units that vest in equal quarterly installments through January 1, 2030, subject to his continuous service.
Idan also directly holds several stock option awards to buy Common Stock, including 68,310 underlying shares at an exercise price of $10.19 per share expiring March 9, 2036, and 104,539 underlying shares at $9.59 per share expiring August 25, 2035. Additional options cover 7,767 shares at $7.88 per share and 129,678 shares at $4.17 per share, with expirations in 2035 and 2034. These options generally vest in 1/48th monthly installments from various start dates, contingent on continued service.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under a Prospectus Supplement No. 6 dated April 29, 2026. The supplement attaches a Form 8-K that discloses a Board and CEO succession and a consulting agreement with former director Dr. Eli Wallace.
The Form 8-K states Pedro J. Beltran, Ph.D. succeeded Dr. Wallace as President and Chief Executive Officer effective April 20, 2026, and the Company entered a consulting agreement effective April 21, 2026 for a twelve-month term that provides for continued vesting of Dr. Wallace’s outstanding equity awards and severance rights under the Company’s Executive Severance Plan.
BridgeBio Oncology Therapeutics, Inc. outlined new arrangements with former President, Chief Executive Officer and director Eli Wallace, Ph.D. The company entered into a Consulting Agreement effective retroactively from April 21, 2026, under which he will advise on research and development programs for 12 months unless ended earlier.
His compensation will be limited to continued vesting of equity awards outstanding as of the effective date, contingent on providing services through each vesting date. Vested stock options may be exercised for up to two years after his service ends or until their original expiration, whichever comes first. Under the company’s Executive Severance Plan and a Separation Agreement and Release, Wallace will also receive Tier 1 officer severance benefits tied to a termination by the company other than for cause.
BridgeBio Oncology Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 16, 2026. Investors will elect two Class I directors, Frank McCormick and Peter Lebowitz, to three-year terms and ratify Deloitte & Touche LLP as auditor for 2026.
The meeting will be held online via webcast, with only stockholders of record as of April 20, 2026, entitled to vote. There were 80,112,725 shares of common stock outstanding on that date, each with one vote. The company uses “notice and access” for proxy materials.
BBOT remains an emerging growth and smaller reporting company and uses scaled executive compensation disclosure. Its board is staggered into three classes, which can make rapid changes of control more difficult. The proxy details director and executive biographies, committee structures, director compensation, and fees paid to Deloitte & Touche LLP and prior auditor Withum.
BridgeBio Oncology Therapeutics, Inc. filed Prospectus Supplement No. 5 registering 63,054,549 shares of Common Stock for resale by the selling securityholders. The supplement incorporates a Form 8-K reporting leadership changes: Pedro Beltran, Ph.D. was appointed President and Chief Executive Officer and joined the Board; Idan Elmelech was appointed Chief Operating Officer and named principal financial officer; Uneek Mehra will depart as CFO with last day April 30, 2026, and Marc Cobo was named principal accounting officer. The supplement references an attached press release and existing executive indemnification and severance plan exhibits.
BridgeBio Oncology Therapeutics, Inc. filed Prospectus Supplement No. 5 registering 63,054,549 shares of Common Stock for resale by the selling securityholders. The supplement incorporates a Form 8-K reporting leadership changes: Pedro Beltran, Ph.D. was appointed President and Chief Executive Officer and joined the Board; Idan Elmelech was appointed Chief Operating Officer and named principal financial officer; Uneek Mehra will depart as CFO with last day April 30, 2026, and Marc Cobo was named principal accounting officer. The supplement references an attached press release and existing executive indemnification and severance plan exhibits.
BridgeBio Oncology Therapeutics, Inc. announced a broad leadership transition. Pedro Beltran, Ph.D., formerly Chief Scientific Officer, has been appointed President, Chief Executive Officer and Class III director, succeeding Eli Wallace, Ph.D., who resigned from the Board and will remain as an advisor.
The Board also promoted Idan Elmelech to Chief Operating Officer and named him principal financial officer, while appointing Marc Cobo as principal accounting officer following the planned departure of CFO Uneek Mehra. In addition, Neil Kumar, Ph.D., was appointed Executive Chairman as the company advances three clinical assets in RAS- and PI3Kα-driven cancers.
BridgeBio Oncology Therapeutics, Inc. announced a broad leadership transition. Pedro Beltran, Ph.D., formerly Chief Scientific Officer, has been appointed President, Chief Executive Officer and Class III director, succeeding Eli Wallace, Ph.D., who resigned from the Board and will remain as an advisor.
The Board also promoted Idan Elmelech to Chief Operating Officer and named him principal financial officer, while appointing Marc Cobo as principal accounting officer following the planned departure of CFO Uneek Mehra. In addition, Neil Kumar, Ph.D., was appointed Executive Chairman as the company advances three clinical assets in RAS- and PI3Kα-driven cancers.